- KR₩174bn
- KR₩259bn
- KR₩465bn
- 42
- 67
- 47
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.37 | ||
| EV to EBITDA | 7.94 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.68% | ||
| Return on Equity | 1.49% | ||
| Operating Margin | 2.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 272,075.38 | 293,018.11 | 340,426.33 | 361,108.56 | 464,874.74 | 437,000 | n/a | 8.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +308.21 | -19.29 | +30.61 | +18.57 | -79.12 | +563.03 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.
Directors
- Do Jun Yoon CHM (66)
- Seol Lee CCE (50)
- Gil Jun Yoon VCH (56)
- Jin Seong Cho OTH (56)
- Chang Sun Lee OTH (58)
- Jae Ho Lee OTH (50)
- Min Gi Jung DRC (53)
- Dae Hyeon Kim DRC (43)
- Hyeong Jin Kim DRC (53)
- Gwang Jun Kim NID (42)
- Mun Cheol Kim NID (53)
- Wu Yeong Shim NID (55)
- Jong Seok Ye NID (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 25th, 1897
- Public Since
- March 24th, 1976
- No. of Shareholders
- 27,524
- No. of Employees
- 723
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 27,717,930
- Address
- 19F, 98, Huam-Ro, Jung-Gu, SEOUL, 04522
- Web
- https://www.dong-wha.co.kr/
- Phone
- +82 220219300
- Auditors
- Hanwool Accounting
Upcoming Events for 000020
Similar to 000020
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 20:18 UTC, shares in Dongwha Pharm Co are trading at KR₩6,270. This share price information is delayed by 15 minutes.
Shares in Dongwha Pharm Co last closed at KR₩6,270 and the price had moved by -27.93% over the past 365 days. In terms of relative price strength the Dongwha Pharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -26.32% over the past year.
The overall consensus recommendation for Dongwha Pharm Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Dongwha Pharm Co dividend yield is 2.87% based on the trailing twelve month period.
Last year, Dongwha Pharm Co paid a total dividend of KR₩180, and it currently has a trailing dividend yield of 2.87%. We do not have any data on when Dongwha Pharm Co is to next pay dividends.
We do not have data on when Dongwha Pharm Co is to next pay dividends. The historic dividend yield on Dongwha Pharm Co shares is currently 2.87%.
To buy shares in Dongwha Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,270, shares in Dongwha Pharm Co had a market capitalisation of KR₩174bn.
Here are the trading details for Dongwha Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 000020
Based on an overall assessment of its quality, value and momentum Dongwha Pharm Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dongwha Pharm Co is KR₩14,000. That is 123.29% above the last closing price of KR₩6,270.
Analysts covering Dongwha Pharm Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,390 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dongwha Pharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -11.96%.
As of the last closing price of KR₩6,270, shares in Dongwha Pharm Co were trading -10.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dongwha Pharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,270.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dongwha Pharm Co's management team is headed by:
- Do Jun Yoon - CHM
- Seol Lee - CCE
- Gil Jun Yoon - VCH
- Jin Seong Cho - OTH
- Chang Sun Lee - OTH
- Jae Ho Lee - OTH
- Min Gi Jung - DRC
- Dae Hyeon Kim - DRC
- Hyeong Jin Kim - DRC
- Gwang Jun Kim - NID
- Mun Cheol Kim - NID
- Wu Yeong Shim - NID
- Jong Seok Ye - NID